DCP
LEGN icon

Davern Capital Partners’s Legend Biotech LEGN Stock Holding History

Davern Capital Partners’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.4M Sell
1,191,522
-123,226
-9% -$3.32M 5.87% 7
2026
Q1 		$23.8M Buy
1,314,748
+258,080
+24% +$4.92M 6.52% 11
2025
Q4 		$23M Buy
+1,056,668
New +$30.3M 7.43% 6

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Davern Capital Partners's LEGN Position: Q2 2026 in Review

Davern Capital Partners reduced its Legend Biotech (LEGN) stake by 9.4% in Q2 2026, selling an estimated $3.32M and leaving 1,191,522 shares worth $34.4M. The position accounts for 5.87% of the portfolio, ranked #7.

Davern Capital Partners first reported a position in LEGN in Q4 2025 and has held it in 3 quarters since. 218 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Davern Capital Partners held 1,191,522 shares of Legend Biotech worth $34.4M as of Q2 2026.
  • Davern Capital Partners sold 123,226 Legend Biotech shares in Q2 2026, an estimated $3.32M.
  • Legend Biotech made up 5.87% of Davern Capital Partners's portfolio in Q2 2026, its #7 holding.
  • Davern Capital Partners first reported a position in Legend Biotech in Q4 2025 and has held it in 3 quarters since.
  • 218 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Davern Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.